- RecruitingPHASE3
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
This study is testing a new drug, AZD2265, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. We want to see if AZD2265 works better than current treatments at slowing down cancer growth and helping men live longer.
For: Metastatic Castration-resistant Prostate CancerUnited States · Australia · Austria - Active not recruitingPHASE2
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
This study is testing a new drug, PF-07220060, for people with advanced cancers like breast, prostate, and lung cancer. Researchers want to see if it's safe and how it works, both by itself and with other cancer medicines.
For: Liposarcoma · Prostate Cancer · Breast NeoplasmsUnited States · Argentina · China - Active not recruitingPHASE3
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
This study looks at a new way to treat prostate cancer that has spread. It compares a drug called enzalutamide with standard treatments to see which works best when started early. We want to find out if enzalutamide can help men newly diagnosed with advanced prostate cancer.
For: Prostatic NeoplasmsUnited States · Australia · Canada - Active not recruitingPHASE3
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
This study is testing a new drug, Saruparib, for men with advanced prostate cancer that is still responding to hormone treatment. It aims to see if adding Saruparib to standard hormone therapy works better than standard therapy alone to slow down cancer growth.
For: Metastatic Castration-Sensitive Prostate CancerUnited States · Australia · Austria - RecruitingPHASE3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
This study looks at a new drug, mevrometostat, combined with enzalutamide for men with prostate cancer that has spread. It compares this combination to enzalutamide alone, to see if it works better for those not yet treated with specific hormone therapies.
For: Metastatic Castration Sensitive Prostate Cancer (mCSPC) · Hormone Sensitive Prostate Cancer · Prostate CancerUnited States · Argentina · Australia - RecruitingPHASE2
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
This study looks at a new drug, Inavolisib, combined with Enzalutamide for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares this combination to other standard treatments.
For: Metastatic Castration-Resistant Prostate CancerUnited States · Australia · Brazil - Active not recruitingPHASE3
Phase III Radium 223 mCRPC-PEACE III
This study is looking at whether using two treatments, Ra223 and enzalutamide, together works better than enzalutamide alone for men with prostate cancer that has spread to their bones. Doctors want to see if this combination can stop the cancer from growing for longer.
For: Prostate CancerBelgium · Brazil · Canada - Active not recruiting
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
This study looks at real-world results for men with prostate cancer that has spread and is sensitive to hormones. It compares two medicines, apalutamide and enzalutamide, which are given alongside standard hormone therapy to see how well they work.
For: Metastatic Hormone-sensitive Prostate CancerAustria · France · Germany - Active not recruitingPHASE3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
This study looks at a new medicine, PF-06821497, combined with enzalutamide for men with advanced prostate cancer that has spread. It compares this combination to standard treatments like enzalutamide or docetaxel to see if it's safer and works better after previous abiraterone treatment.
For: Metastatic Castrate Resistant Prostate Cancer (mCRPC)United States · Argentina · Australia - Active not recruitingPHASE3
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
This study looks at a medicine called enzalutamide for men with prostate cancer that hasn't spread but is high-risk. It aims to see if adding enzalutamide to standard hormone therapy and radiation helps prevent the cancer from coming back.
For: Prostatic NeoplasmsUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
This study is testing new treatments, alone or in combination, for advanced prostate cancer that has spread and no longer responds to hormone therapy. Researchers want to see if these treatments are safe and effective in helping men with this condition.
For: Castration-Resistant Prostatic Cancer · MetastasisUnited States · Argentina · Australia - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
This study is looking into a new drug, PF-06821497, combined with an existing drug, enzalutamide, for men with advanced prostate cancer. It wants to see if this combination works better than enzalutamide alone for those who haven't had certain other treatments.
For: Metastatic Castration-Resistant Prostate CancerUnited States · Argentina · Brazil - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
This study looks at a new drug, BMS-986365, for men with prostate cancer that has spread and is no longer responding to hormone treatment. We want to see if it works better and is safer than standard treatments chosen by doctors.
For: Metastatic Castration-resistant Prostate CancerUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
This study is testing a new medicine, Tulmimetostat, for people with advanced cancers like solid tumours and lymphomas. It's looking at how safe it is, any side effects, and if it helps to shrink tumours.
For: Advanced Solid Tumor · Diffuse Large B Cell Lymphoma · Lymphoma, T-CellUnited States · France · Italy - RecruitingPHASE3
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
This study looks at a new drug, 177Lu-TLX591, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. It compares this new drug combined with standard treatments to standard treatments alone.
For: Metastatic Castration-resistant Prostate CancerUnited States · Australia · Canada - RecruitingPHASE2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
This study is for men with prostate cancer who are already taking enzalutamide as part of another research study. It aims to gather more information on the long-term safety of enzalutamide when it's helping them. Participants will continue their current treatment and have regular check-ups.
For: Prostate CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This study looks at a new combination of drugs, cabozantinib and atezolizumab, for men with prostate cancer that has spread and is no longer responding to hormone therapy. It compares this new combination with standard hormone treatments to see if it works better.
For: Metastatic Prostate Cancer · Prostate AdenocarcinomaUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
This study compares a new medicine, opevesostat, with existing treatments like abiraterone or enzalutamide for prostate cancer that has spread and is no longer responding well to standard hormone therapy. It aims to see if opevesostat is safer and more effective at stopping cancer growth.
For: Metastatic Castration-resistant Prostate Cancer (mCRPC) · Prostatic NeoplasmsUnited States · Australia · Brazil - RecruitingPHASE3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This study is testing a new medicine, Opevesostat, for men with prostate cancer that has spread and is resistant to hormone treatment. We want to see if Opevesostat helps men live longer compared to standard hormone therapies, especially after they've had other treatments.
For: Prostate Cancer MetastaticUnited States · Argentina · Australia - Active not recruitingPHASE2, PHASE3
Management of Castration-Resistant Prostate Cancer with Oligometastases
This study looks at a new way to treat advanced prostate cancer that has spread to a few places. It tests if adding special radiation (SBRT) to standard hormone therapy can delay the cancer from getting worse and put off other treatments.
For: Castration-resistant Prostate Cancer Patients with OligometastasesCanada - Active not recruitingPHASE2, PHASE3
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
This study, called STAMPEDE, looks for better ways to treat prostate cancer that is spreading or has a high chance of spreading. It tests new treatments against standard ones to help men live longer and have a better quality of life.
For: Prostate CancerSwitzerland · United Kingdom - Active not recruitingPHASE3
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
This study looks at a new treatment, [Lu-177]-PNT2002, for advanced prostate cancer that has spread and isn't responding to standard hormone therapy. It compares this new treatment with existing hormone therapies to see if it can slow down cancer growth.
For: Metastatic Castration-Resistant Prostate CancerUnited States · Canada · France - RecruitingPHASE2
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
This study looks at a new drug, JSB462, with existing treatments (abiraterone or enzalutamide) for men with advanced prostate cancer that is still sensitive to hormone therapy. It aims to find the best dose and check how well it works and if it's safe.
For: Metastatic Hormone-sensitive Prostate CancerUnited States · Australia · Brazil - RecruitingPHASE2
Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
This study looks at treating prostate cancer that has spread. We want to see if adding an extra tablet called enzalutamide to standard radiation and hormone therapy improves quality of life. It’s for men whose cancer has spread a little, but not too far, and they don’t want continuous hormone therapy.
For: Metastatic Prostate CancerCanada - Active not recruitingPHASE1, PHASE2
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
This study is looking at a new drug, AZD5305, combined with existing hormone therapies for men with prostate cancer that has spread. It aims to see if the combination is safe, how the body handles it, and if it helps treat the cancer.
For: Metastatic Prostate CancerUnited States · Australia · Italy - Active not recruitingPHASE3
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
This study allows some cancer patients who are already benefiting from certain treatments in another study to continue receiving that treatment. It’s for those who wouldn't be able to get the treatment otherwise, helping them keep accessing therapies that are working for them.
For: CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
This study looks at a new combination of medicines, enzalutamide and leuprolide, for men with prostate cancer that hasn't spread but is considered high-risk. The goal is to see how safe and effective this combination is in slowing down the cancer.
For: Hormone Sensitive Prostate Cancer · Prostate Cancer · Cancer of the ProstateUnited States · Australia · Austria - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
This study looks at a new combination of drugs, pembrolizumab and enzalutamide, for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares this combination to enzalutamide alone to see if it helps men live longer and stops the cancer from growing.
For: Prostatic NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
This study is looking at a new medicine called Xaluritamig for men with advanced prostate cancer that has stopped responding to standard hormone therapy. It compares Xaluritamig to existing treatments like Cabazitaxel or other hormone therapies, to see which is more effective at helping men live longer.
For: Metastatic Castration-resistant Prostate CancerUnited States · Australia · Austria